T细胞受体
生物
细胞生物学
T细胞
癌症研究
CD8型
免疫系统
抗原
癌症
免疫学
遗传学
作者
Mojdeh Shakiba,Paul Zumbo,Gabriel Espinosa-Carrasco,Laura Menocal,Friederike Dündar,Sandra E. Carson,Emmanuel M. Bruno,Francisco J. Sánchez‐Rivera,Scott W. Lowe,Steven Camara,Richard P. Koche,Vincent Reuter,Nicholas D. Socci,Benjamin M. Whitlock,Fella Tamzalit,Morgan Huse,Matthew D. Hellmann,Daniel K. Wells,Nadine Defranoux,Doron Betel,Mary Philip,Andrea Schietinger
摘要
T cell receptor (TCR) signal strength is a key determinant of T cell responses. We developed a cancer mouse model in which tumor-specific CD8 T cells (TST cells) encounter tumor antigens with varying TCR signal strength. High-signal-strength interactions caused TST cells to up-regulate inhibitory receptors (IRs), lose effector function, and establish a dysfunction-associated molecular program. TST cells undergoing low-signal-strength interactions also up-regulated IRs, including PD1, but retained a cell-intrinsic functional state. Surprisingly, neither high- nor low-signal-strength interactions led to tumor control in vivo, revealing two distinct mechanisms by which PD1hi TST cells permit tumor escape; high signal strength drives dysfunction, while low signal strength results in functional inertness, where the signal strength is too low to mediate effective cancer cell killing by functional TST cells. CRISPR-Cas9–mediated fine-tuning of signal strength to an intermediate range improved anti-tumor activity in vivo. Our study defines the role of TCR signal strength in TST cell function, with important implications for T cell–based cancer immunotherapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI